These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 28760063)

  • 1. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
    J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
    Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
    Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants.
    Fermann GJ; Lovelace B; Christoph MJ; Lingohr-Smith M; Lin J; Deitelzweig SB
    J Med Econ; 2020 Dec; 23(12):1409-1417. PubMed ID: 33054507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
    Rozjabek HM; Coleman CI; Ashton V; Laliberté F; Oyefesobi P; Lejeune D; Germain G; Schein JR; Yuan Z; Lefebvre P; Peterson ED
    J Med Econ; 2019 Aug; 22(8):751-759. PubMed ID: 30939954
    [No Abstract]   [Full Text] [Related]  

  • 6. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
    Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
    J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
    Stankovic P; Georgiew R; Frommelt C; Hammel S; Wittlinger J; Hoch S; Obradovic D; Dagres N; Wilhelm T
    J Thromb Thrombolysis; 2019 Apr; 47(3):384-391. PubMed ID: 30729376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation.
    Dobry P; McGrew K; Yun I; Heath R; Shafqat A; Ascend-Higher ; Giuliano C
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1039-1050. PubMed ID: 38507060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
    Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
    Dhamane AD; Baker CL; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Curr Med Res Opin; 2019 Oct; 35(10):1769-1776. PubMed ID: 31120309
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
    Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
    J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.